Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer - FINCHANNEL

Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer - FINCHANNEL

NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) breast cancer following induction treatment. The approval expands the use […]

Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer

NEW YORK--(BUSINESS WIRE)--Oct 7, 2026-

FDA approves Pfizer’s Tukysa regimen for metastatic breast cancer

This regimen is indicated for adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) disease following induction treatment. The regulatory decision introduces an oral The post FDA approves Pfizer’s Tukysa regimen for metastatic breast cancer appeared first on Pharmaceutical Business review.

FDA Approves Tukysa Plus Trastuzumab and Pertuzumab as First-Line Maintenance Treatment for HER2-Positive Metastatic Breast Cancer

Tukysa adds a chemotherapy-free maintenance option for HER2-positive metastatic breast cancer; liver toxicity monitoring remains a key consideration.

FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer

Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.